These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34114943)

  • 1. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
    Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
    Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
    [No Abstract]   [Full Text] [Related]  

  • 2. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
    Gertz MA; Vaxman I
    Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
    Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
    J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
    [No Abstract]   [Full Text] [Related]  

  • 4. Smoldering Myeloma and the Art of War.
    Lonial S; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
    [No Abstract]   [Full Text] [Related]  

  • 5. Regression of smoldering myeloma with treatment of Gaucher disease.
    Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
    Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of systemic sclerosis coexisting with smoldering myeloma.
    Smoleńska Ż; Gogulska Z; Dorniak K; Zdrojewski Z
    Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34698468
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistent challenges with treating multiple myeloma early.
    Goodman AM; Kim MS; Prasad V
    Blood; 2021 Jan; 137(4):456-458. PubMed ID: 33236046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Difficulty in Defining the True High-Risk Smoldering Myeloma.
    Weinhold N; Rasche L
    Clin Cancer Res; 2024 Oct; 30(19):4263-4265. PubMed ID: 39047171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of CD56 expression in smoldering myeloma patients on early progression.
    Notarfranchi L; Segreto R; Vescovini R; Dalla Palma AB; Marchica V; Burroughs-Garcia J; Toscani D; Todaro G; Raimondi V; Iannozzi NT; Bonomini S; Sammarelli G; Craviotto L; Pedrazzoni M; Storti P; Giuliani N
    Hematol Oncol; 2023 Aug; 41(3):587-589. PubMed ID: 36441875
    [No Abstract]   [Full Text] [Related]  

  • 11. Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma.
    Werly A; Hampel M; Hielscher T; Zuern K; Schmidt SK; Visram A; Raab MS; Mueller-Tidow C; Goldschmidt H; Mai EK
    Blood Cancer J; 2024 Oct; 14(1):176. PubMed ID: 39402047
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoldering Myeloma Treatment: Who, What, and When.
    Mejia Saldarriaga M; Rossi A
    Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic patterns of progression in smoldering multiple myeloma.
    Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
    Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoldering multiple myeloma: taking the narrow over the wide path?
    Avet-Loiseau H; Bahlis NJ
    Blood; 2024 May; 143(20):2025-2028. PubMed ID: 38427775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
    Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
    Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
    [No Abstract]   [Full Text] [Related]  

  • 18. Population screening for smoldering multiple myeloma reveals high prevalence.
    Nat Med; 2023 Feb; 29(2):313-314. PubMed ID: 36755165
    [No Abstract]   [Full Text] [Related]  

  • 19. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.